All articles by GlobalData
GlobalData
@globaldataplc
Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo
Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).
Chinese checkpoint inhibitors are poised to change global IO markets
The Chinese Government’s significant R&D investments in recent years has resulted in the successful commercialisation and launch of several domestically developed therapeutic agents.
Turning point: November marked by promising Covid-19 vaccine development data
With the global devastation of Covid-19 continuing into 2021, the month of November marks a turning point in the pandemic timeline. A number of sponsors have released Phase III vaccine trial results in this month with all vaccines displaying good efficacy and generally well-tolerated safety profiles
Jardiance fails to deliver in EMPERIAL trials for heart failure
The trial failure places doubt on the success of Jardiance in further trials for HF-REF and HF-PEF and may impact the uptake of the drug.
Astellas expands into gene therapy with $3bn acquisition of Audentes
The acquisition of Audentes will allow Astellas to expand into a fifth primary focus area: genetic regulation.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain
Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
IDWeek 2019: Long-acting antiretroviral therapy shows promise for HIV patients with low adherence
HIV infections can be well controlled with antiretroviral therapy to a degree where the viral load is not detectable anymore.
Global Blood Therapeutics leads in world sickle cell disease trials
Sickle cell disease comprises a group of inherited disorders caused by mutations of haemoglobin subunit beta.
Trends in clinical trials for gene therapies in neurology
84% of gene therapy trials happening in various neurology indications, listed in GlobalData’s Pharma Intelligence Center, are in early-stage development, that is Phase I, Phase I/II, and Phase II.
Top ten drugs in biosimilar trials globally
The number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira.